GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. [PDF]
Diabetes Metab Syndr ObesAbid M, Sheikh KS, Ahmad MS, Jiang H.
europepmc +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, EarlyView.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
More than a sidekick: GIP signalling and cardiovascular outcomes. [PDF]
Eur Heart JKurt B, Kahles F.
europepmc +1 more source
The Journal of AMDNegli ultimi anni, l’obesità è stata ridefinita come una malattia cronica, recidivante e multifattoriale, superando il modello obsoleto del semplice squilibrio energetico. Questa nuova visione ha coinciso con una rivoluzione terapeutica guidata dalla farmacoterapia su base incretinica.
openaire +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, EarlyView.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy? [PDF]
Curr Hypertens RepKylies D, Dreher L, Wenzel UO.
europepmc +1 more source
Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction
Obesity Reviews, EarlyView.Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey +7 more
wiley +1 more source
Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved β-cell function: a case report suggesting acquired incretin resistance. [PDF]
Cardiovasc Diabetol Endocrinol RepPrasad S +6 more
europepmc +1 more source
Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists. [PDF]
J Diabetes InvestigKubota S, Seino Y, Yabe D.
europepmc +1 more source